Krognes Steve E.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Jul 3, 2024
- Accession no.
- 0001714899-24-000156
- Filed
- Jul 3, 2024
- Trade date
- Jun 13-Jul 1, 2024
- Filing delay
- 20 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $678.7K. It was filed 20 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krognes Steve E.CIK 0001666236 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 13, 2024 | Common Stock | SSaleDisposed | −688 | $21.79 | −$14,991.52 | 52,620 | Direct | |
| Jul 1, 2024 | Common Stock | SSaleDisposed | −29,900 | $22.12 | −$661,388 | 34,504 | Direct | |
| Jul 1, 2024 | Common Stock | SSaleDisposed | −100 | $22.80 | −$2,280 | 34,404 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.